In a sample of 400 phase II trials that included 25,000 participants, a total of 4,045 patients (16.2%) received a treatment ...
Monroe Biomedical Research (MBR), a dedicated clinical trial site, is growing its footprint to enhance early-phase clinical ...
Metsera Inc. (MTSR), a New York-based biotech that went public on Jan. 31 with some fanfare, has a full portfolio of weight-loss drugs in development, using both the hormones already used in existing ...
Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter ...
Fear of nuclear fallout has led to a novel therapeutic approach that could significantly extend the lives of individuals with ...
Find out how the virtual biotech company Libra Therapeutics leveraged data to accelerate drug development for ...
AMLX has had major setbacks in its lifecycle, including the voluntary withdrawal of an approved drug. Click here to find out ...
The ultimate goal is to develop the facility wherein Hawaii cancer patients will no longer need to travel out of state for ...
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
Early-phase clinical trials, including phase 1 and some phase 2a studies, serve as a pivotal step for biotech companies, laying the foundation for a drug candidate’s journey to market.
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers at Mayo Clinic are exploring the use of a new drug called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results